Evoke Pharma (NASDAQ:EVOK – Get Free Report) will likely be issuing its quarterly earnings data on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $3.08 million for the quarter.
Evoke Pharma Stock Up 9.4 %
Shares of NASDAQ:EVOK opened at $3.96 on Wednesday. The company has a market capitalization of $5.88 million, a P/E ratio of -0.36 and a beta of 0.16. The stock’s fifty day simple moving average is $4.67 and its 200-day simple moving average is $4.76. Evoke Pharma has a 52-week low of $3.44 and a 52-week high of $12.32.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on Evoke Pharma in a report on Tuesday. They issued a “sell” rating for the company.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- GitLab: Get In While It’s Down—Big Rebound Ahead
- What Investors Need to Know to Beat the Market
- Tesla Stock: Finding a Bottom May Take Time
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
